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A subset of non-small cell lung cancer (NSCLC), which does not have a druggable driver mutation, is treated with
platinum-based cytotoxic chemotherapy, but it develops resistance triggered by DNA damage responses. Here, we
investigated the effect of activation of STAT3 by cisplatin on anti-apoptotic proteins and the effectiveness of a co-
treatment with cisplatin and a BH3 mimetic, ABT-737. We analyzed the relationship between cisplatin and STAT3
pathway and effect of ABT-737, when combined with cisplatin in NSCLC cells and K-ras mutant mouse models. The
synergism of this combination was evaluated by the Chou-Talalay Combination Index method. In vivo activity was
evaluated by micro-CT. In NSCLC cells, there was a time and dose-dependent phosphorylation of SRC-JAK2-STAT3 by
cisplatin, followedby increased expression of anti-apoptoticmolecules.When the expression of theBCL-2 protein family
members was evaluated in clinical samples, BCL-xL was most frequently overexpressed. Dominant negative STAT3
suppressed their expression, suggesting that STAT3 mediates cisplatin mediated overexpression of the anti-apoptotic
molecules. ABT-737 displaced BCL-xL from mitochondria and induced oligomerization of BAK. ABT-737 itself showed
cytotoxic effects and a combination of ABT-737 with cisplatin showed strong synergistic cytotoxicity. In a murine lung
cancer model, co-treatment with ABT-737 and cisplatin induced significant tumor regression. These findings reveal a
synergistic cytotoxic and anti-tumor activity of ABT-737 and cisplatin co-treatment in preclinicalmodels, and suggest that
clinical trials using this strategy may be beneficial in advanced NSCLC.
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Lung cancer is a common and leading cause of cancer death worldwide.
In the year 2012, 1,824,701 new lung cancer were diagnosed, and
1,590,000 patients died of this devastating disease worldwide [1].
Advanced stage of lung cancer, which does not have a druggable driver
mutation, is treated with platinum based-cytotoxic chemotherapy, but
clinical outcome is suboptimal.
Cisplatin is a prototypic platinum chemotherapeutic agent and one
of the most commonly prescribed drugs for the treatment of solid
malignancies; however, its therapeutic benefits are often limited because
of multiple resistance mechanisms. These resistancemechanisms can be
classified by the alterations of steps (1) delivering cisplatin to DNA
(pre-target resistance), (2) forming DNA-cisplatin adducts (on-target
resistance) (3) related to cell death pathways elicited by DNA damage
responses (post-target resistance) and (4) affecting signaling pathwaysthat do not have obvious links with cisplatin treatment (off-target
resistance) [2].
Overexpression of antiapoptotic members of the BCL-2 protein
family is a cause for poor responses to chemotherapeutic agents and is
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Alterations in cell death pathway induced by DNA damage responses
is one of the critical mechanisms related to chemoresistance, and
therefore, modulation or bypass of these responses might be an
effective way in improving treatment outcomes [5,6]. Influence of
MAPK pathway activation on cisplatin mediated apoptotic pathway is
well established, but the relationship between JAK2-STAT3 pathway
and response to cisplatin mediated cytotoxicity is limited (7).
Considering the role of STAT3 as an oncogene and that activation
of its signaling confers resistance to apoptosis, it is important to
identify the relationship and to develop effective control modality.
Inactivation of BCL-2 family proteins might overcome the resistance
against cisplatin-mediated apoptosis and may improve clinical outcomes.
BH3-only proteins of BCL-2 family can directly or indirectly activate the
effector protein of the mitochondrial membrane permeabilization. In the
indirect (displacement) model, the BH3-only proteins (NOXA, BAD
andBIM) insert their a-helical BH3 domain into the hydrophobic groove
of prosurvival proteins. In the direct activationmodel, BH3-only proteins
are classified into “sensitizer” and “activator”. In this model, the activator
BH3-only proteins (BIM, tBID) are sequestered by prosurvival proteins.
The subsequent interaction between the prosurvival proteins and
“sensitizer” BH3-only proteins (BAD, NOXA) releases the “activator”
proteins [7]. In both model, the binding of BH3-only proteins to
prosurvival molecules results in BAX/BAK conformation change,
oligomerization and mitochondrial membrane permeabilization [8,9].
BH3 mimetics show a biochemical affinity for specific anti-apoptotic
BCL-2 proteins and this is linked to their ability to kill specific cells.
Several clinical trials have been performed using BH3 mimetics, such as
ABT-737, ABT-263, AT-101, GX15-070, and TW-37, with limited
success [10]. We hypothesize that a combination of cisplatin with
prototypic BH3 mimetics, ABT-737, would overcome the cisplatin
resistance caused by STAT3 activation.
In this study, we investigated the relationship between cisplatin and
STAT3 pathway and effect of ABT-737, prototype of BH3 mimetics,
when combined with cisplatin in non-small cell lung cancer (NSCLC)
cells and aK-rasmutantmousemodels. The synergismof this combination
was evaluated by the Chou-Talalay Combination Index (CI) method. In
vivo activity was evaluated by microCT and showed that this combination
can be effectively applied for the treatment of lung cancer.
Materials and Methods
Cell Lines, Plasmids, Clinical Specimens, Chemicals, and Antibodies
A549 and H1703 cells were purchased from ATCC (Manassas, VA,
USA) in 2012. H460, H1299, H358, H2009, and H596 cells were
obtained from the Korean Cell Line Bank in 2012 (https://cellbank.snu.
ac.kr/main/, Seoul, Korea), which provides cell test and authentication by
DNA fingerprinting analysis by short tandem repeat markers and
mycoplasma contamination test. Except for the experiment for revision,
cells were used within six months after purchase. EF.GFP (#17616),
EF.STAT3DN.Ubc.GFP (#24984), pCDNA3 Flag MKK7B2Jnk1a1
(#19726), and, pCDNA3 Flag MKK7B2Jnk1a1(APF) (#19730), were
obtained from Addgene (Cambridge, MA, USA) and pcDNA3 were
obtained from Invitrogen (Carlsbad, CA, USA). Anisomycin (ab120495)
was purchased from Abcam (Cambridge, UK) and dasatinib (# S1021)
was purchased from Selleckchem (Houston, TX, USA). To evaluate
expression of anti-apoptotic proteins in humanNSCLC, 12-paired lysates
from adjacent normal appearing lung tissue and cancer-enriched tissue
were analyzed by immunoblotting. Another set of 117 formalin-fixed
paraffin embedded (FFPE) NSCLC tissue were used for immunohisto-chemistry (IHC). This study was approved by the IRB of Gangnam
Severance Hospital (IRB #3–2014-0299) and was carried out in
accordance with theDeclaration ofHelsinki andKoreanGCP guidelines.
ABT-737was purchased from theAdooQ™Bioscience (Irvine, CA,USA)
and its chemical and crystal structure was described in elsewhere [11,12].
Antibodies, unless otherwise stated, were obtained from Cell Signaling
Technology (Danvers, MA, USA).
Immunoblotting
Cells were harvested on ice using 2×Laemmli sample buffer
containing protease and phosphatase inhibitors (Sigma-Aldrich). After
sonication, 30–50 mg of lysate was separated by gel electrophoresis on
7.5 to 12% polyacrylamide gels and transferred onto nitrocellulose
membranes (Bio-Rad Laboratories, Inc., Richmond, CA, USA). The
expression level of each protein was measured using ImageJ (http://
rsbweb.nih.gov/ij/) and quantified relative to that of β-actin [5].
RT-PCR
The RT-PCR was performed as described elsewhere [13]. Total
RNA was extracted using TRI reagent (Ambion, Austin, TX, USA).
Quantitative RT-PCR analysis was performed using TaqMan Gene
Expression assay reagents and the StepOnePlus Real-Time PCR
system (Applied Biosystems, Carlsbad, CA, USA) using an
inventoried primer-probe set (http://bioinfo.appliedbiosystems.com/
genome-database/gene-expression.html).
Mitochondrial Cytochrome c Release Assay
Cells were harvested and suspended in cell permeability buffer and
incubated on ice for 10minutes [14]. Cell disruption was performed by
pipetting and vortexing. The homogenates were spun at 700×g for
10 min at 4°C. The supernatants were transferred to a fresh tube and
spun at 13,000×g for 10 min at 4°C. The supernatants (cytosolic
fraction) were transferred to a new tube and the mitochondrial pellets
were resuspended in cell permeability buffer. After sonication, lysates
were resolved on a 15% polyacrylamide gel, and analyzed by
immunoblotting using a mouse anti-cytochrome c antibody.
Cell Death, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) Assay, and Drug Combination Study
To measure cell death, cells were treated with the indicated dose of
ABT-737 and cisplatin for 48 h, then stained with annexin-V and
propidium iodide (PI) and analyzed using a FACSCanto II flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The effect of
treatment on cell proliferation was assessed by the MTT assay. Briefly,
5 × 105 cells per well were treated with either ABT-737 (0–80 μM),
cisplatin (0–160 μM), or a combination of both drugs at fixed
concentration ratios of 1:0.5, 1:1, and 1:2 (cisplatin:ABT-737). After
48 h, MTT was added at a final concentration of 0.5 mg/mL, and cells
were incubated for an additional 2 h at 37°C. Formazan complexes were
dissolved in DMSO, and absorbance was measured at 550 nm with a
spectrophotometer (Thermo Scientific, Rockford, IL, USA). The effect
of combining the therapies was evaluated with a CI previously proposed
by Chou-Talalay using CompuSyn software (CompuSyn) [15].
Immunocytochemistry
Cells (5 × 105) were plated in 6-well plates containing a sterilized
coverslip. On the following day, cells were fixed with 4% formaldehyde
in PBS, incubated in blocking solution containing 5% BSA in PBS,
and then incubated with anti-cytochome c, anti-BAK and anti-Bcl-xL
antibodies for 16 hours. On the following day, the cells were washed, and
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added. Mitochondria were stained with MitoTracker Red CMXRos
(red). The nuclei were counterstained with DAPI (blue) (1:1000) in PBS
and imaged using an LMS 710 confocal microscope (Carl Zeiss,
Oberkochen, Germany). Images were acquired using ZEN 2012,
Version 8,0,0,273 imaging software (Carl Zeiss, Oberkochen, Germany).
Mouse Imaging
LSL K-ras G12D mice were obtained from the NCI mouse
repository (http://mouse.ncifcrf.gov/), bred, and genotyped according
to the supplier's guidelines. This animal study was approved by our
Institutional Animal Care andUse Committee, following the guidelines
of the American Association for the Assessment and Accreditation of
Laboratory Animal Care. AdCre virus was obtained from the Gene
Transfer Vector Core of the University of Iowa (Iowa City, IA, USA).
LSLK-rasG12Dmice inhaled 5 × 107 PFUAdCre virus at eight weeks
after birth [16], 24 ± 2 weeks after AdCre particle inhalation, a
micro-CT was taken using a small animal eXplore Locus microCT (GE
Healthcare, Little Chalfont, UK) under isoflurane anesthesia (45 μm
resolution, 80 kV, 450 μA current). The mice were categorized into
three groups according to tumor burden (mild, moderate, or severe),
and then randomized within the same severity group to receive either
vehicle (30% polyethylene glycol, 5% TWEEN 80, and 65% of 5DW
solution), ABT-737 (50 mg/kg, i.p., daily), cisplatin (5 mg/kg, i.p.,
weekly), or a combination of both drugs for two weeks. Treatment
response was evaluated by CT image analysis. To measure the area of
tumor, first, three representative CT images per mouse were selected at
the upper, middle, and lower levels of the lung. Then, the tumor area
was quantified in pixels using Adobe Photoshop (Adobe Systems,
San Jose, CA) and Paint.Net (dotPDN, LLC, Kirkland, WA) software.A
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Figure 1. Cisplatin induces overexpression of anti-apoptotic proteins.
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IHC
FFPE human NSCLC tissues and mice tissues, sacrificed after the
second micro-CT, were analyzed by IHC using the LABS 2 System
(Dako, Carpinteria, CA, USA) according to the manufacturer's
instructions. Briefly, sections were deparaffinized, rehydrated, immersed
in 3% H2O2 in methanol solution, and then incubated overnight with
primary antibodies against activated caspase-3 in antibody diluent (Dako)
at a 1:100 dilution. Sections were incubated for 10 minutes with
biotinylated linker and processed using avidin/biotin IHC techniques.
3,3′-Diaminobenzidine (DAB) was used as a chromogen in conjunction
with the LiquidDABSubstrate kit (Novacastra, UK). BCL-xL expression
was evaluated by a semiquantitative approach [17]. The staining intensity
of BCL-xL was evaluated with reference to that of normal appearing
adjacent tissues such as bronchial epithelia cells and alveolar macrophages
as follows: 0; negative, 1; buff, 2; yellow (similar staining intensity to
bronchial epithelial cells), 3; dark brown. The frequency of stained cancer
cells was scored as follows: 0; b5%, 1; b25%, 2; b50%, 3; b75%, 4;
~100%. The percentage of positively stained cancer cells and staining
intensities were multiplied to generate immunostaining score. The
staining scores 0, 1 to 3, 4 to 8, and ≥9 were considered negative, trace,
moderate, and strong expression, respectively.
Statistical Analysis
Independent sample t-tests were used for univariate analysis of
continuous variables.Difference of tumor area change among groupswas
analyzed by Mann–Whitney U test. Predictive factors for disease-free
survival (DFS) and overall survival (OS) were calculated using the(kD)
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Table 2. Clinical and Pathological Characteristics of 117 NSCLC Cases Used for IHC Analysis
Clinical Characteristics Cytoplasmic Expression (n = 117)
Negative/Trace (n = 31) Positive (n = 86) P-value
Gender
Male 25 62 0.350
Female 6 24
Smoking status 0.811
Never smokers 6 23
Ever smokers 22 55
Maximal diameter of tumor (㎝) 4.2 ± 1.94 4.2 ± 2.09 0.976
pStage 0.708
I 12 26
II 7 20
III 12 38
IV 0 2
Pathologic diagnosis 0.237
Adenocarcinoma 12 47
Squamous cell carcinoma 19 38
Others 0 1
Smoking status of 11 cases was unknown.
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for statistical analysis. All statistical analyses were two-tailed and p-values
of less than 0.05 were interpreted to indicate statistical significance.
Results
Increased Expression of Anti-Apoptotic Proteins After
Cisplatin Treatment
Alterations in apoptotic pathway by cisplatin induced DNA damage
responses are frequently observed after treatment of cisplatin and have
been estimated to be a major cause of treatment failure [18,19]. To
confirm this, NSCLC cells were treated with cisplatin and expression of
anti-apoptotic protein was evaluated by immunoblotting using
phosphorylation of H2AX at Ser139 as a cisplatin-induced DNA
double strand breakage marker. There was dose and time dependent
overexpression of BCL-2 family member proteins after cisplatin
treatment (Figure 1, A and B). To determine the increase in
anti-apoptotic molecules at the transcriptional level after cisplatin
treatment, A549 andH460 cells were treated with cisplatin for 6 and 16
h and mRNA expression of anti-apoptotic molecules was evaluated by
real time PCR (RT-PCR). The mRNA levels of the anti-apoptotic
molecules increased and reached a peak at 6 h after treatment after
which they decreased. Among them, BCL-w mRNA levels increased
more than those of the othermolecules did (Figure 1C). Taken together,
cisplatin induced overexpression of BCL-2 family member of
anti-apoptotic protein occurred at the transcriptional level in part.
Anti-Apoptotic Proteins are Frequently Overexpressed
in NSCLC
To evaluate overexpression of anti-apoptotic proteins in NSCLC,
immunoblotting was performed using a set of paired cancer enriched
and normal appearing adjacent tissue lysates from 12 NSCLC patients
(Table 1 and Figure 1D). Among the 12 pairs, eight cases (66.7%)
showed increased expression of BCL-xL in the lung cancer enriched
tissue lysates when compared in the lysate of adjacent normal appearing
lung tissues, followed by BCL-2 andMCL-1 overexpression in five pairs
(41.7%) respectively. BCL-w showed weak expression in the two cases,
which did not differ between the cancer-enriched and adjacent tissue
lysates, and overexpression in the cancer lysate in one case.
Because BCL-xL was the one, which was specifically expressed in
cancer-enriched tissue lysates with high frequency, its clinical implicationTable 1. Demographic Characteristics of the NSCLC Cases Used for Immunoblotting
Random
No.
Gender Age Histology Differentiation Smoking TNM Stage
A01 F 76 Adeno n.s* Never smoker T3N0M0 IIB
A02 F 48 Adeno acinar type Never smoker T1aN2M0 IIIA
A03 M 75 Adeno solid predominant Ex-smoker T2aN0M0 IB
A04 F 75 Adeno papillary
predominant
Never smoker T1bN0M0 IA
A05 M 67 Squamous n.s* Never smoker T2aN0M0 IB
A06 M 68 Squamous moderate Current smoker T2aN1M0 IIA
A07 M 65 Squamous poorly Ex-smoker T2aN0M0 IB
A08 M 62 Adeno micropapillary
predominant pattern
Ex-smoker T2aN1M0 IIA
A09 M 59 Adeno micropapillary
predominant with
mucin formation
Current smoker T2aN2M0 IIIA
A10 M 71 Adeno acinar predominant Current smoker T1bN2M0 IIIA
A11 M 66 Squamous moderate Ex-smoker T2bN2M0 IIIA
A12 F 74 Adeno acinar predominant Never smoker T2aN0M0 IB
n.s; not specified.was evaluated in 117 FFPE NSCLC tissues by IHC. The demographic
characteristics of the 117 NSCLC cases were described in the Table 2.
BCL-xL was mainly expressed in the cytoplasm of lung cancer cells
(Figure 2A). A total of 88 (75.2%) NSCLC cases showed positive
BCL-xL expression, which was comparable to the results of immuno-
blotting (Figure 2B). Then the clinical outcome of the study cases was
analyzed according to the expression of BCL-xL. Although the difference
of DFS and OS did not reach statistical significance between negative/
trace vs. positive expression group, there were clear separation of survival
curve between groups (Figure 2C). These findings are also observed in a
subset analysis using the cases who underwent adjuvant chemotherapy
after curative resection (data not shown). Taken together, anti-apoptotic
proteins were specifically overexpressed in NSCLC cancer tissues and
overexpression of BCL-xL was most frequent.
STAT3 Mediates Cisplatin-Induced Elevation of
Anti-Apoptotic Molecules
To identify the underlying mechanism that induces overexpression of
the antiapoptotic protein family, NSCLC cell lines, A549 and H460,
were treated with various doses and times of cisplatin and the
phosphorylation of JNK and SRC was evaluated. After cisplatin
treatment, phosphorylation of JNK and SRC increased, reaching a peak
after about 24 h, followed by a decrease (Figure 3, A–C). To determine
whether the elevation of antiapoptotic proteins was mediated by JNK1,
A549 and H460 cells were transfected with constitutive active form of
JNK1 (MKK7-JNK1) and kinase dead form (MKK7-JNK1(APF)).
These cells were also treated with the JNK1-specific activator,
anisomycin, and evaluated using the same methods (Figure 3D). No
differences were noted in the expression of antiapoptotic proteins
between constitutive active and kinase dead transfected cells. After
anisomycin treatment, the expression of BCL-xL and other
anti-apoptotic molecules decreased, suggesting that the elevation of
the anti-apoptotic molecules was not mediated by JNK. Further, to
confirm whether the increased expression of anti-apoptotic protein is
mediated by STAT3 activation, the effect of SRC phosphorylation was
evaluated by immunoblotting. The phosphorylation of SRCwas relayed
to phosphorylation of STAT3 through JAK2 with the passage of time
(Figure 3E). The dominant negative form of STAT3, EF.STAT3DN,
was then transfected, and the effect on expression of BCL-xL and
other anti-apoptotic molecules was evaluated by immunoblotting.
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EF.STAT3DN. When the EF.STAT3DN transfected A549 and
H1299 cells were treated with cisplatin, the increase in the levels of
the anti-apoptotic molecules was blunted (Figure 3F). To determine the
effect on the expression of BCL-xL by cisplatin mediated activation of
SRC pathway, additional experiment was performed using SRC
inhibitor, dasatinib (Figure 3G). Pretreatment of dasatinib suppressed
elevation of pSTAT3 by cisplatin, leading inhibition of BCL-xL
expression. These findings suggest that the increase in BCL-2 protein
family is caused by cisplatin-mediated STAT3 activation.
Cisplatin Potentiates Inherent Characteristics of BH3 Mimetics
ABT-737, a small-molecule BH3 mimetic, disrupts the BCL-2/BAK
complex and BAK-dependent activation of the intrinsic apoptotic
pathway [20]. First, to identify the inherent characteristic of the
ABT-737, A549 cells were treated with ABT-737, and subcellular
fractionation was performed. Cytochrome c was released from the
mitochondria and accumulated in the cytosol after ABT-737 treatment
in a dose- and time-dependentmanner (Figure 4A). Confocalmicroscopy
revealed that ABT-737 displaced BCL-xL from mitochondria and
induced aggregation BAK signal and co-localization at mitochondria. It
also showed that ABT-737 displaced cytochrome c from mitochondria
into cytoplasm, and this effect was not influenced when combined with
cisplatin treatment (Figure 4B). To clarify the effect of combination on
cytochrome c release, immunoblotting on subcellular fraction was
performed (Figure 4C). Displacement of cytochrome c from mitochon-
drial fraction to cytoplasmwasmore evident by combination treatment in
the immunoblotting. Taken together, cisplatin treatment did not disturb
inherent characteristic of BH3 mimetics but potentiated.
Synergy of Cisplatin and BH3 Mimetics
The effect of this combination was further evaluated whether these
molecular findings lead to synergistic effect on cell death usingimmunoblotting, flow cytometer, and tetrazolium-based colorimetric
(MTT) assay and CI was obtained by the method proposed by
Chou-Talalay [15]. As demonstrated by immunoblotting and flow
cytometric analysis of cell death, the combination of cisplatin and
ABT-737 potentiated the cytotoxic effects of cisplatin (Figure 5, A and
B). To determine the synergistic effect of both drugs by cell death assay,
A549 and H460 cells were treated with 1:1 fixed ratios of cisplatin to
ABT-737 for 48 h, and cell death was measured by flow cytometer by
the Annexin V-PI staining. Statistically significant increment in cell
death occurred in the combination treatment group (Figure 5C), and CI
was obtained by the Chou-Talalay method (Supplementary Figure S1).
To further determine whether the increase in cell death was the
synergistic effect of the cisplatin and ABT-737 at various concentration
and to find out optimal combination condition, both drugs were
combined at fixed dose ratios and the MTT assay was performed. The
CI–F(a) and Dose–F(a) curves generated from the MTT assay results
demonstrated a strong synergism in A549 cells and a synergism inH460
cells when combination therapy was used (Figure 5,D and E). To further
confirm the synergistic effect of both drugs, additional experiments were
performed using five different NSCLC cell lines, H1299, H358,
H2009, H1703, and H596. Strong synergism was observed in H596
cells and synergism was shown in other NSCLC cell lines
(Supplementary Figure S2).
Combination Effect of Cisplatin and BH3 Mimetics in
Animal Model
To validate the effect of combination treatment in vivo, 34 ±
2 week-old mice that had been infected with AdCre by inhalation
were randomized and treated with vehicle, cisplatin (5 mg/kg, i.p.,
weekly), ABT-737 (50 mg/kg, i.p., daily), or a combination of both
drugs (Figure 6A). Response was measured by micro-CT (Figure 6B).
Statistically significant reductions in tumor size occurred in the
combination treatment group (P = .029; Mann–Whitney U test)
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Figure 3. STAT3 mediates cisplatin-induced elevation of anti-apoptotic molecules. (A) A549 and H460 cells were treated with indicated
dose of cisplatin for 16 h and the phosphorylation of JNK and SRC was evaluated by immunoblotting. (B) A549 and H460 cells were
treated with 3 μM of cisplatin for indicated times and phosphorylation of JNK and SRC was evaluated by immunoblotting. (C) A549 and
H460 cells were treated with indicated doses and times of cisplatin and evaluated using the samemethods. (D) A549 and H460 cells were
transfected with constitutive active form of JNK (MKK-JNK1), kinase dead form (MKK-JNK1(APF)) and treated with JNK1-specific activator,
anisomycin. Phosphorylation of JNK and expression of anti-apoptotic molecules was evaluated by immunoblotting. (E) A549 and H460
cells were treated with cisplatin for indicated times and phosphorylation of SRC, JAK2 and STAT3 was evaluated by immunoblotting.
(F) A549 and H1299 cells were transfected with dominant negative form of STAT3, EF.STAT3DN, and treated with or without cisplatin.
Expression of anti-apoptotic molecules was evaluated by immunoblotting. (G) A549 and H460 cells were treated with 3 μM of cisplatin
and/or 50 nM of SRC inhibitor, dasatinib, for 16 h. Expression of p-SRC, pSTAT3 and BCL-xL were evaluated by immunoblotting. Actin was
used as a loading control and p-H2AX (Ser139) were used as a marker for cisplatin mediated DNA damage. *A549 cells do not express
BCL-2 (http://www.proteinatlas.org/ENSG00000171791-BCL2/cell/CAB000003).
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H&E and immunohistochemistry (Figure 6, D and E). Together
with morphologic changes in the combination treatment group,
showing shrunken cytoplasm and condensed nuclei, expression of
activated caspase-3 was more frequently detected in the combination
groups. In summary, a significant tumor reduction was observed after
two weeks in LSL K-ras G12D mice following combined treatment
with cisplatin and ABT-737 compared to treatment with vehicle or
either agent alone. To determine the toxicity of ABT-737, mousebody weight was measured daily. Weight loss in the combination
group was not significantly different compared to the monotherapy
groups; combination treatment with cisplatin and ABT-737 is thus a
tolerable treatment (Figure 6, F and G).
Because p53 plays a major role in the initiation of the apoptotic
pathway in DNA damaged cells, additional experiments were
performed using LSL K-ras G12D:p53fl/fl mice (Supplementary
Figure S3). The median survival of this model is about 14 weeks after
AdCre inhalation and tumors show aggressive phenotypes with high
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2 week-old), the mice were treated and evaluated in the same manner
as in LSL K-ras G12D mice. Although it did not reach statistical
significance, combination treatment group showed reduced tumor
burden when compared with cisplatin or ABT-737 monotherapy
group, which is consistent to the findings in LSL K-ras G12D mice
model. Morphologic changes, which indicates apoptosis, were
frequently observed and expression of activated caspase-3 was
statistically higher in the lung of combination group, suggesting
that this combination is effective in the cancer with p53 loss.
Discussion
Targeted treatment strategies focusing on the genetic variation of a
specific gene are of limited use for the treatment of a subset of lung
cancer, in which druggable driver mutation was not identified,
suggesting that new strategies aiming the common elements of cancer
are required. One of the hallmarks of cancer is its ability to resist cell
death using various mechanisms to circumvent the apoptotic pathway
[6]. Besides loss of function of TP53 tumor suppressor, which induces
apoptosis of critically damaged cells [22], decreased function of
proapoptotic factors (BAX, BIM, and PUMA), and elevation of
antiapoptotic regulators (BCL-2, BCL-xL, and BCL-w) are frequently
observed [2]. The aberrant regulation of the apoptotic pathway is notonly an inherent characteristic of the cancer cells, but it can be induced
by drug treatment and influences drug sensitivity.
Platinum-based chemotherapeutic agents have been extensively
used for the treatment of solid tumors, and the resistance mechanisms
against these agents have been studied widely [2,23]. However,
reports on the effects of apoptosis protein expression by cisplatin
treatment are limited. Cisplatin-mediated increase in the activity of
MAPK family members was clearly observed in a dose- and
time-dependent manner in various in vitro and in vivo experimental
settings. Studies have shown varying effects of increased ERK1, JNK,
and STAT3 activities on cisplatin sensitivity. A recent meta-analysis
concluded that, depending on the experimental setting, increased
JNK activity can either increase [24–27] or decrease sensitivity
[28,29] to cisplatin treatment. However, previous studies were based
mostly on cell culture assays and the results from in vivo systems are
limited, indicating that animal studies are required to provide a
conclusive relationship between JNK activity and cisplatin. In our
study, by using lung cancer cell lines, the JNK inhibitor SP600125
was not able to induce growth inhibition in the MTT assay even
when using concentrations of up to 80 μM but it potentiated the
cytotoxic effect of cisplatin when both agents were combined (data
not shown). With these findings, a negligible effect on the expression of
anti-apoptotic proteins suggests that the activation of JNK might not
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indicating that cisplatin affects the gene expression of ubiquitin-
proteasome system and inhibits activity of proteasome [30,31]. In the
experiments with bortezomib, 20S proteasome inhibition broadly
influences on the expression of BCL-2 family protein [32,33]. These
reports suggest that the inhibition of the proteasome pathway by
cisplatin might be another of increased expression of BCL-xL, but
requires further studies to connect cisplatin treatment and BCL-2
family protein expression. STAT3 is one of key downstream mediators
of activated EGFR and is activated by various signals such as interferon,
IL-5, and IL-6. It plays multiple roles in tumorigenesis involving
inflammation, stem cells, and pre-metastatic niche [34]. Ameta-analysis
by Xu et al. showed that high STAT3 or pSTAT3 expression is a strong
predictor of poor prognosis in NSCLC patients [35]. Although the
underlying mechanism that relates over-expression of STAT3 and poor
clinical outcome is not well established, our in vitro experiments
suggested that it might be related to the expression of anti-apoptoticproteins. Further prospective translational studies may be warranted to
substantiate this.
The advantages of combination chemotherapy include the
emergence of synergistic interaction effects, the ability to overcome
of multidrug resistant clones, and the reduction of the drug dose with
a concomitant diminished toxicity to healthy tissues [36,37]. The
general principles of cancer drug combinations are to (1) use drugs
with non-overlapping toxicities, (2) combine agents with different
mechanisms of action and minimal cross-resistance, (3) preferentially
use drugs with proven activity as single drugs, and (4) administer the
combination at early-stage disease and at a schedule with a minimal
treatment-free period between cycles, but allowing the recovery of
sensitive target tissues. Based on this classical principle, co-treatment
with cisplatin and BH3 mimetics would be an optimal combination
regimen for the treatment of lung cancer.
Based on these findings, application of BH3 mimetics for the
treatment of lung cancer seems to be promising; however, the
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treatment was modest [38]. It may be attribute to that ABT-737 was
not easy to be administered up to the maximum doses because of
toxicity. Because survival of platelet is dependent to BCL-xL,
thrombocytopenia is one of major adverse effects of the ABT-737
treatment [39]. In this study, the hematologic profile was evaluated in
a subset of mice at the end of treatment (Supplementary Table 1).
Significant thrombocytopenia was observed in the mice treated with
the cisplatin and combination regimen. This suggests that risk of
bleeding events could be further increased in the combination
regimen containing cisplatin, and that further studies on the dosing
and treatment schedules are required. Because of concerns about
hematologic toxicities, there are attempts to improve pharmaceutical
formulation such as nanoencapsulation of ABT-737. These strategies
expect to reduce the toxicity and enhance efficacy of combination
treatment with ABT-737 [40]. In addition, selective, oral BCL-2
inhibitor sparing platelets, ABT-199, was developed and studied in
several ongoing trials with single or combination regimens [41].Another useful method for evaluating the efficacy of this new
regimen is to determine if the treatment prolongs survival. For this
purpose, a few mice treated with the combination regimen have been
monitored for their overall survival. Because of the limited number of
the mice, the full statistics could not be obtained. The median survival
duration of combination treatment group was 6.3 months from
treatment and this indicates that additional methods to test the
efficacy of the combination treatment, such as observation of
progression free survival with repeated imaging, may be required.
In conclusion, we investigated the changes in the levels of
anti-apoptotic molecules mediated by cisplatin-induced STAT3
activation in depth. Additionally, we found that co-treatment with
BH3mimetics could help to bypass cisplatin resistance. Themodulation
of the apoptotic pathway, which determines the cell fate of damaged cells,
with BH3 mimetics would be an effective way to overcome the barriers
in NSCLC treatment caused by intratumoral heterogeneity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2017.02.008.
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